GLP1R and type 2 diabetes mellitus: Illustrating the translational potential of stimulating cardiac glucose oxidation as an approach for DbCM, glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonists are a glucose-lowering drug class that improve cardiovascular outcomes in people with T2D [107], and these agents increase cardiac glucose oxidation rates in mice with HFD/low-dose STZ-mediated DbCM [58].